Xencor, Inc. (NASDAQ:XNCR) Shares Acquired by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P increased its position in Xencor, Inc. (NASDAQ:XNCR) by 21.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,092,346 shares of the biopharmaceutical company’s stock after buying an additional 192,080 shares during the quarter. Loomis Sayles & Co. L P owned about 1.56% of Xencor worth $25,102,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares during the last quarter. Quarry LP grew its holdings in shares of Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 2,108 shares during the period. KBC Group NV increased its position in Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 813 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,337 shares during the period. Finally, Rockefeller Capital Management L.P. acquired a new position in Xencor during the third quarter valued at approximately $205,000.

Xencor Stock Performance

Shares of XNCR stock opened at $11.51 on Friday. The company’s fifty day moving average price is $15.72 and its two-hundred day moving average price is $20.14. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a market capitalization of $811.02 million, a P/E ratio of -3.60 and a beta of 0.74. Xencor, Inc. has a 12 month low of $10.90 and a 12 month high of $27.24.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. On average, research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on XNCR. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and increased their price target for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Finally, Wells Fargo & Company cut their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average price target of $34.38.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.